Market Closed - Japan Exchange 14:30:00 12/06/2026 HKT 5-day change 1st Jan Change
1,688.50 JPY -1.97% Intraday chart for Nipro Corporation -3.49% +14.32%
Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Nipro Corporation

Market Cap 275B 1.72B 1.48B 1.37B 1.28B 2.4B 163B 2.44B 16.16B 6.3B 79.53B 6.45B 6.31B P/E Ratio 2026
18.7x
P/E Ratio 2027 * 20.1x
Enterprise Value 771B 4.81B 4.16B 3.83B 3.58B 6.72B 457B 6.82B 45.22B 17.63B 223B 18.06B 17.67B EV / Sales 2026
0.38x
EV / Sales 2027 * 1.12x
Free-Float
87.38%
Yield 2026
1.87%
Yield 2027 * 1.92%
05-12 Nipro Corporation Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2026 and Fiscal Year Ending March 31, 2027 CI
05-12 Nipro Corporation Announces Year-End Dividend for Fiscal Year Ended March 31, 2026, Payable on June 10, 2026; Provides Second Quarter-End and Year-End Dividend Guidance for Fiscal Year Ending March 31, 2027 CI
05-01 Jefferies Adjusts Nipro's Price Target to 1,500 Yen From 1,300 Yen, Keeps at Hold MT
03-11 Nipro Fixes Record Date for Fiscal 2026 Year-End Dividend MT
02-09 Nipro Corporation Reports Earnings Results for the Nine Months Ended December 31, 2025 CI
12-24 Nipro Corporation Announces Establishment of Wholly Owned Subsidiary in Singapore CI
11-10 Nipro Corporation Announces Dividend for the Second Quarter End of Fiscal Year Ending March 31, 2026, Payable on December 10, 2025 CI
10/06/25 Samsung Bioepis Partners With Nipro to Commercialize Biosimilars in Japan MT
09/06/25 Samsung Bioepis Co., Ltd. Enters into A Strategic Partnership with NIPRO Corporation for Commercialization of Multiple Biosimilars in Japan CI
13/05/25 Jefferies Adjusts Nipro's Price Target to 1,300 Yen from 1,400 Yen, Keeps at Hold MT
12/05/25 Nipro Corporation Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2025 and Fiscal Year Ending March 31, 2026 CI
12/05/25 Nipro Corporation Announces Dividend for the Year Ended March 31, 2025, Effective June 27, 2025; Provides Dividend Guidance for the Second Quarter End of Fiscal Year Ending March 31, 2026 CI
12/05/25 Nipro Corporation Provides Dividend Guidance for the Fiscal Year Ending March 31, 2026 CI
1 day-1.97%
1 week-3.49%
Current month-1.89%
1 month+15.61%
3 months+12.01%
6 months+16.37%
Current year+14.32%
1 week 1,682
Extreme 1682
1,754.5
1 month 1,598.5
Extreme 1598.5
1,760.5
Current year 1,401
Extreme 1401
1,760.5
1 year 1,230.5
Extreme 1230.5
1,760.5
3 years 1,001.5
Extreme 1001.5
1,760.5
5 years 987
Extreme 987
1,760.5
10 years 908
Extreme 908
1,760.5
Manager TitleAgeSince
President 58 26/06/2025
Chief Administrative Officer 57 26/06/2025
Corporate Officer/Principal - -
Director TitleAgeSince
Chairman 81 26/06/2025
Director/Board Member 53 01/06/2009
Director/Board Member 58 01/06/2009
Change 5-day change 1-year change 3-year change Capi.($)
-1.97%-3.49%+31.50%+67.43% 1.72B
-1.64%-3.17%-35.38%-13.04% 154B
-0.16%-1.80%-9.37%-4.84% 103B
+0.07%+2.41%-4.53%+57.08% 54.8B
+3.00%+0.30%+55.27%+51.53% 55.22B
-0.75%-3.25%-16.18%-41.67% 40.3B
-1.40%+8.93% - - 30.96B
+0.16%+3.44%-9.03%-40.61% 29.08B
-0.46%+4.55%+46.20%-7.99% 23.23B
-2.85%-3.53%-16.97%-1.50% 20.25B
Average -0.43%+0.57%+4.61%+7.38% 51.21B
Weighted average by Cap. +0.03%-0.32%-7.74%+1.07%

Financials

2026 2027 *
Net sales 662B 4.13B 3.57B 3.29B 3.08B 5.77B 393B 5.85B 38.81B 15.13B 191B 15.5B 15.17B 699B 4.36B 3.77B 3.47B 3.25B 6.09B 415B 6.18B 40.99B 15.98B 202B 16.37B 16.02B
Net income 14.65B 91.44M 78.98M 72.78M 68.13M 128M 8.69B 130M 859M 335M 4.23B 343M 336M 14.32B 89.42M 77.23M 71.17M 66.62M 125M 8.5B 127M 840M 328M 4.14B 336M 328M
Net Debt 495B 3.09B 2.67B 2.46B 2.3B 4.32B 294B 4.38B 29.06B 11.33B 143B 11.61B 11.36B 504B 3.15B 2.72B 2.51B 2.34B 4.39B 299B 4.46B 29.58B 11.53B 146B 11.81B 11.56B
Logo Nipro Corporation
Nipro Corp is a Japan-based company mainly engaged in the medical, pharmaceutical, and pharma packaging businesses. It has three segments. The Medical segment consists of the domestic business division and the international business division. The domestic business division sells medical devices related to injections and infusions, artificial organs, high-performance medicines, and dialysis. The international business division, centered on the head office, has medical device manufacturing and sales bases overseas for regional expansion, selling medical devices related to injections and infusions, artificial organs, and diabetes. The Pharmaceutical segment sells pharmaceuticals related to kit preparation containers on a contract basis from pharmaceutical companies. The Pharma Packaging segment sells medical glass products such as glass tubes and ampoules, thermos flasks, and kit preparation containers in Japan.
Employees
39,168
Date Price Change Volume
12/06/26 1,688.50 ¥ -1.97% 749,300
11/06/26 1,722.50 ¥ -0.83% 586,900
10/06/26 1,737.00 ¥ +1.85% 632,300
09/06/26 1,705.50 ¥ -1.13% 613,100
08/06/26 1,725.00 ¥ -1.40% 607,200
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
1,688.50JPY
Average target price
1,816.00JPY
Spread / Average Target
+7.55%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 8086 Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!